Menu Search
Equities

Oryzon Genomics SA

ORN:MUN

Oryzon Genomics SA

Actions
  • Price (EUR)1.63
  • Today's Change0.000 / 0.00%
  • Shares traded--
  • 1 Year change-19.01%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-3.99m
  • Incorporated--
  • Employees43.00
  • Location
    Oryzon Genomics SASant Ferran 74CORNELLA DE LLOBREGAT 08940SpainESP
  • Phone+34 935151313
  • Fax+34 933774028
  • Websitehttp://www.oryzon.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.